INmune Bio and Anthony Nolan expand partnership to develop advanced stem cell therapies for RDEB, cancer, and inflammatory diseases

INmune Bio and UK charity Anthony Nolan have expanded their collaboration to enhance the CORDStrom™ MSC platform, using high-quality umbilical cord tissue to develop consistent, scalable cell therapies. This partnership targets treatments for Recessive Dystrophic Epidermolysis Bullosa (RDEB), oncology, and inflammatory diseases like osteoarthritis and lupus. The agreement ensures regulatory compliance and quality standards, leveraging Anthony Nolan's expertise in stem cell sourcing. This strategic move aims to overcome previous challenges in MSC therapy consistency and advance new treatments toward commercial approval.